Source: ALL
Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1236
Gene Symbol: CCR7
CCR7
0.010 Biomarker phenotype BEFREE (iv) Our studies in CCR7(-/-) mice showed improved survival and attenuated increase in markers of myocardial dysfunction and wall stress in post-MI HF after 1 week, accompanied by increased myocardial expression of markers of regulatory T cells. 22427939 2012
Entrez Id: 6343
Gene Symbol: SCT
SCT
0.010 GeneticVariation phenotype BEFREE 29 men post-MI participants were randomly assigned to either 12-weeks of CAT (n = 15) or SCT (n = 14). 29377893 2018
Entrez Id: 10631
Gene Symbol: POSTN
POSTN
0.010 Biomarker phenotype BEFREE Post-MI fibrosis was smaller in periostin knockout adult mice than in wildtype mice, while glycogen synthase kinase 3β was increased and cyclin D1 was decreased in periostin knockout mice. 29872491 2018
Entrez Id: 595
Gene Symbol: CCND1
CCND1
0.010 Biomarker phenotype BEFREE Post-MI fibrosis was smaller in periostin knockout adult mice than in wildtype mice, while glycogen synthase kinase 3β was increased and cyclin D1 was decreased in periostin knockout mice. 29872491 2018
Entrez Id: 7019
Gene Symbol: TFAM
TFAM
0.010 AlteredExpression phenotype BEFREE TFAM overexpression could ameliorate the decrease in mtDNA copy number and mitochondrial complex enzyme activities in post-MI hearts. 16043643 2005
Entrez Id: 4803
Gene Symbol: NGF
NGF
0.010 Biomarker phenotype BEFREE NGF elicits pleiotropic beneficial actions in the post-MI heart. 20360245 2010
Entrez Id: 1557
Gene Symbol: CYP2C19
CYP2C19
0.010 GeneticVariation phenotype BEFREE CYP2C19 loss-of-function but not PON1 variants were significantly associated with increased risk of major cardiovascular events (death, MI, and urgent coronary revascularization) occurring during long-term clopidogrel exposure in 371 young post-MI patients (age <45 years) enrolled in the AFIJI cohort (CYP2C19 loss-of-function allele carrier versus noncarrier: hazard ratio, 2.26; 95% confidence interval, 1.15-4.41, P=0.02; PON1 QQ192 versus QR/RR192: hazard ratio, 1.03; 95% confidence interval, 0.50-2.11, P=0.93; PON1 LL55 versus LM/MM55: hazard ratio, 1.52; 95% confidence interval, 0.75-3.08, P=0.24). 21972404 2011
Entrez Id: 7490
Gene Symbol: WT1
WT1
0.010 Biomarker phenotype BEFREE Wilms tumor-1 (Wt1)-positive epicardial cells were higher in hSCF/tetracycline transactivator compared with wild-type mice 3 days post MI. 25107671 2014
Entrez Id: 4303
Gene Symbol: FOXO4
FOXO4
0.010 Biomarker phenotype BEFREE FoxO4(-/-) mice had a significantly higher post-MI survival, better cardiac function, and reduced infarct size. 26438688 2015
Entrez Id: 5747
Gene Symbol: PTK2
PTK2
0.010 Biomarker phenotype BEFREE FAK has recently received attention as a potential mediator of fibrosis, our previous study reported that pharmacological inhibition of FAK can attenuate cardiac fibrosis in post MI models. 28225063 2017
Entrez Id: 6778
Gene Symbol: STAT6
STAT6
0.020 Biomarker phenotype BEFREE STAT6-knockout (STAT6<sup>-/-</sup>) mice had a phenotype similar to that of HDC<sup>-/-</sup> mice post-MI; however, in contrast to HDC<sup>-/-</sup> mice, the beneficial effects of exogenous histamine injections were abrogated in STAT6<sup>-/-</sup> mice. 28272448 2017
Entrez Id: 7078
Gene Symbol: TIMP3
TIMP3
0.010 AlteredExpression phenotype BEFREE TIMP3 overexpression blunted the early rise in proteolytic activities post-MI. 28550172 2017
Entrez Id: 2739
Gene Symbol: GLO1
GLO1
0.010 Biomarker phenotype BEFREE GLO1 over-expression reduced MG-AGE levels at 6 h and 4 weeks, and GLO1 mice exhibited superior cardiac function at 4 weeks post-MI compared to WT mice. 28864889 2017
Entrez Id: 3934
Gene Symbol: LCN2
LCN2
0.030 Biomarker phenotype BEFREE NGAL knockout mice with MI had lower LV interstitial fibrosis and inflammation, better LV contractility and compliance, and greater stroke volume and cardiac output than wild-type mice with MI at 3 months post-MI. 29061727 2017
Entrez Id: 10036
Gene Symbol: CHAF1A
CHAF1A
0.010 Biomarker phenotype BEFREE CAF identifies new high-risk post-MI patients with LVEF >35% which might benefit from prophylactic strategies. 29121716 2017
Entrez Id: 8850
Gene Symbol: KAT2B
KAT2B
0.010 Biomarker phenotype BEFREE CAF identifies new high-risk post-MI patients with LVEF >35% which might benefit from prophylactic strategies. 29121716 2017
Entrez Id: 407008
Gene Symbol: MIR223
MIR223
0.020 Biomarker phenotype BEFREE MicroRNA-223 (miR-223) expression has been reported to be altered in post-MI heart failure in humans; however, the roles of miR-223 in MI remain unknown. 29689569 2018
Entrez Id: 6696
Gene Symbol: SPP1
SPP1
0.010 Biomarker phenotype BEFREE Spp1 knockout mice showed vulnerability to developing post-MI left ventricular chamber dilatation and the terminal deoxynucleo-tidyltransferase 2'-Deoxyuridine-5'-triphosphate nick-end labeling (TUNEL)-positive cells in the infarcted myocardium after MI remained higher in number in Spp1 knockout mice than in wild-type mice. 29967195 2018
Entrez Id: 10411
Gene Symbol: RAPGEF3
RAPGEF3
0.010 Biomarker phenotype BEFREE Epac1-activation reduces cardiac dysfunction and LA fibrosis post-MI. 30016400 2019
Entrez Id: 6423
Gene Symbol: SFRP2
SFRP2
0.010 AlteredExpression phenotype BEFREE Sfrp2 both enhanced and sustained cardiomyocyte-specific gene expression in the in vivo c-Kit(+) cells: expression of cardiomyocyte-specific transcripts was higher and there was no decline in expression by 12 days post-MI. 30171847 2018
Entrez Id: 3458
Gene Symbol: IFNG
IFNG
0.010 Biomarker phenotype BEFREE IFN-γ directs a sequential chemotactic cellular immune response and determines survival and cardiac function post-MI. 30949687 2019
Entrez Id: 10724
Gene Symbol: OGA
OGA
0.020 AlteredExpression phenotype BEFREE OGA expression was significantly upregulated at 4-week post-MI but overall protein O-GlcNAcylation was not changed. 31152247 2019
Entrez Id: 2358
Gene Symbol: FPR2
FPR2
0.010 Biomarker phenotype BEFREE FPR2 antagonist WRW4 (1 μg/kg/day) was subcutaneously injected 3 h post-MI maintaining saline-injected MI-controls. 31216426 2019
Entrez Id: 338872
Gene Symbol: C1QTNF9
C1QTNF9
0.020 Biomarker phenotype BEFREE CTRP9 markedly ameliorated macrophage infiltration and attenuated the inflammatory responses by downregulating interleukin-1β and interleukin-6, and upregulating interleukin-10, in 3 days post-MI; depressed left atrial fibrosis by decreasing the expressions of collagen types I and III, α-SMA, and transforming growth factor β1 in 7 days post-MI possibly through depressing the Toll-like receptor 4/nuclear factor-κB and Smad2/3 signaling pathways. 31623508 2019
Entrez Id: 23569
Gene Symbol: PADI4
PADI4
0.010 Biomarker phenotype BEFREE PAD4 deficiency aggravates acute inflammation and increases tissue damage post-MI, partially due to the lack of NETs. 31632398 2019